Sellbyville, DE -- (SBWIRE) -- 04/26/2019 -- Global Pet Cancer Therapeutics Market to exceed USD 300 million by 2024, as per a new research report by Global Market Insights, Inc. Growing pet adoption rate coupled with increasing disposable income of pet owners will drive market growth. Strong and robust drug pipeline for treatment of pet cancer will stimulate business growth over the forecast years. Rising number of pet dogs suffering from cancer will spur orthopedic implants and devices demand. According to American Veterinary Cancer Society, nearly 50% of dogs over the age of 10 have cancer and die of it. The need to control cancer in pets and pet owners will to save their pet from cancer is a major reason behind development in cancer therapeutics.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2017

Companies in pet cancer therapeutics market have been working toward launching new drugs for cancer treatments to increase the survival rates in the animals. The newly developed UMN drug referred as eBAT was successfully tested on 23 dogs of different breeds at the University of Minnesota, the outcome of which indicated a rise in the survival rates of dogs affected from Hemangiosarcoma (HSA) cancer.

During the trials, canines were injected with eBAT thrice before chemotherapy and after performing surgeries for tumor removal. The therapy raised the survival rate of the pet animals to 70% - a factor which may cause pet cancer therapeutics market players to sit up and explore potential growth opportunities. Besides, five of the 23 dogs, who were treated with eBAT, survived for over 450 days. HSA being a blood vessel based cancer type, necessitated the use of the UMN drug for the clinical test, as it can target both, the vascular system and cancer tumor.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Zoetis Inc.
- Merial
- Aratana Therapeutics Inc.
- AB Science
- Regeneus Ltd
- Oasmia Pharmaceutical AB
- VetDC, Inc.
- CanFel Therapeutics

Dating back to 2014, Advaxis, a biotechnology and healthcare firm based in the U.S., had discovered a drug called ADXS-cHER2 and successfully treated the 18 dogs affected from osteosarcoma at the Pennsylvania School of Veterinary Medicine. During the clinical tests, 9 out of 18 dogs depicted positive immunological responses. It was later discovered that more than two-third of the dogs who were treated with the drug survived for a prolonged period. These drug trials depict that new inventions in the field of pet cancer technology are certain to augment pet cancer therapeutics market share.

Speaking of another novel collaboration in pet cancer therapeutics industry, in December 2015, Spotlight Innovation Incorporation, had formed a subsidiary firm named as CDT Veterinary Therapeutics Incorporation to detect new cancer treatment methods in pets. The latter had emphasized on the commercialization of Crotalin, a drug comprising cytotoxic proteins, endowed with the ability to eliminate animal cancer cells. The move offers more opportunities for other key business players to explore various dimensions of cancer treatment, thereby providing a positive impetus to pet cancer therapeutics industry. As per Global Market Insights, Inc., pet cancer therapeutics industry is slated to produce a revenue of more than USD 300 million by 2024, growing at a rate of over 10% over 2017-2024.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2017

Strategic alliances and joint ventures are the prime growth strategies of pet cancer therapeutic industry. In 2016, Aratana Therapeutics Incorporation, a U.S. based pharmaceutical firm, had entered an alliance with Elanco, a division of Eli Lilly & Company. According to the strategic agreement, the latter was provided with the rights to expand its pet animal product portfolio across the U.S.

Chapter 1. Methodology

1.1. Methodology

1.2. Market definition

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary

1.4.1.1. Paid sources

1.4.1.2. Unpaid sources

1.4.2. Primary

Browse Full Report Details @ https://www.gminsights.com/industry-analysis/pet-cancer-therapeutics-market

Chapter 2. Executive Summary

2.1. Pet cancer therapeutics industry 3600 synopsis, 2014 - 2025

2.1.1. Business trends

2.1.2. Medicine type trends

2.1.3. Species trends

2.1.4. Cancer type trends

2.1.5. Regional trends

Related Report- Biosensors Market By Type, By Technology, By Medical Application, Regional Outlook, Application Development Potential, Competitive Market Share & Forecast, 2018 – 2024

Know more@ https://www.marketwatch.com/press-release/biosensors-market-technological-advancement-growth-analysis-with-forecast-to-2024-2019-04-25